Connect-to-Translate
Ksilink has created a unique Association that offers full alignment from KOLs to PCC generation
Together with partners and key opinion leaders (KOL), Ksilink has built up a proven alliance of competence bridging academic excellence to leading development capacities.
Staying at the cutting edge of clinical know-how and development
Ksilink has created a strategic alliance – the Ksilink Association – with leading European institutions and their KOL’s. This competence network offers Ksilink privileged access to stem cells derived from patients and patient cohorts as well as cutting edge technologies and latest clinical developments.
Associating the most competent partners in each disease area
From high scale standardized production of differentiated patient-based cells to preclinical development of novel molecular entities: the Ksilink Association builds a translational hub gathering most competent partners in each area.
Securing translational feasibility
Contributing to an integrated value chain, our partners ensure translational feasibility and market access. Partners are connected to Ksilink through different gateways, from a specific project collaboration to a membership within the Ksilink Association. Ksilink’s network is constantly expanding and allow us to address drug discovery challenges as a team.
The Ksilink Association: Connecting in the long run!
Scientific achievements require team spirit, time and consistency. The Ksilink Association allows for a multidisciplinary effort to foster patient-based drug discovery, increasing our chances to effectively translate scientific excellence into new treatments for patients.
The Association consists of 12 permanent members:
- Academia:
Inserm, Université de Strasbourg, ZI Mannheim, University of Mannheim, DKFZ - Industry & Pharma:
Sanofi, Lead Discovery Center, Life & Brain, myriamed GmbH - Patients’ organizations:
AFM-Téléthon - Clusters:
BioValley France, BioPro Baden-Württemberg